EMPA-KIDNEY. A Multicentre International Randomized Parallel Group Double-Blind Placebo-Controlled Clinical Trial of Empagliflozin Once Daily To Assess Cardio-Renal Outcomes in Patients With Chronic Kidney Disease
Awarded By
- Boehringer Ingelheim/University of Oxford
Contributors
- Green, Jennifer Brigitte Principal Investigator, US Coordinating Center
Start/End
- 2017